Search

Your search keyword '"Senesse P"' showing total 43 results
Start Over Author "Senesse P" Search Limiters Available in Library Collection
43 results on '"Senesse P"'

2. Operational definition of Active and Healthy Ageing (AHA): A conceptual framework

Author

Bousquet, Jean, Kuh, D., Bewick, M., Standberg, T., Farrell, J., Pengelly, R., Joel, M.E., Rodriguez Mañas, L., Mercier, J., Bringer, J., Camuzat, T., Bourret, R., Bedbrook, A., Kowalski, M.L., Samolinski, B., Bonini, S., Brayne, C., Michel, J.P., Venne, J., Viriot-Durandal, P., Alonso, J., Avignon, A., Ben-Shlomo, Y., Bousquet, P.J., Combe, B., Cooper, R., Hardy, R., Iaccarino, G., Keil, T., Kesse-Guyot, E., Momas, I., Ritchie, K., Robine, J.M., Thijs, C., Tischer, C., Vellas, B., Zaidi, A., Alonso, F., Andersen Ranberg, K., Andreeva, V., Ankri, J., Arnavielhe, S., Arshad, H., Augé, P., Berr, C., Bertone, P., Blain, H., Blasimme, A., Buijs, G.J., Caimmi, D., Carriazo, A., Cesario, A., Coletta, J., Cosco, T., Criton, M., Cuisinier, F., Demoly, P., Fernandez-Nocelo, S., Fougère, B., Garcia-Aymerich, J., Goldberg, M., Guldemond, N., Gutter, Z., Harman, D., Hendry, A., Heve, D., Illario, M., Jeande, C., Krauss-Etschmann, S., Krys, O., Kula, D., Laune, D., Lehmann, S., Maier, D., Malva, J., Matignon, P., Melen, E., Mercier, G., Moda, G., Nizinkska, A., Nogues, M., O'Neill, M., Pelissier, J.Y., Poethig, D., Porta, D., Postma, D., Puisieux, F., Richards, M., Robalo-Cordeiro, C., Romano, V., Roubille, F., Schulz, H., Scott, A., Senesse, P., Slagter, S., Smit, H.A., Somekh, D., Stafford, M., Suanzes, J., Todo-Bom, A., Touchon, J., Traver-Salcedo, V., Van Beurden, M., Varraso, R., Vergara, I., Villalba-Mora, E., Wilson, N., Wouters, E., and Zins, M.

Published
2015
Full Text
View/download PDF

5. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer

Author

Bécouarn, Y., Senesse, P., Thézenas, S., Boucher, E., Adenis, A., Cany, L., Jacob, J.H., Cvitkovic, F., Montoto-Grillot, C., and Ychou, M.

Published
2007
Full Text
View/download PDF

6. Operational definition of Active and Healthy Ageing (AHA) : A conceptual framework

Author

Bousquet, J., Kuh, D., Bewick, M., Standberg, T., Farrell, J., Pengelly, R., Joel, M. E., Rodriguez Manas, L., Mercier, J., Bringer, J., Camuzat, T., Bourret, R., Bedbrook, A., Kowalski, M. L., Samolinski, B., Bonini, S., Brayne, C., Michel, J. P., Venne, J., Viriot-Durandal, P., Alonso, J., Avignon, A., Ben-Shlomo, Y., Bousquet, P. J., Combe, B., Cooper, R., Hardy, R., Iaccarino, G., Keil, T., Kesse-Guyot, E., Momas, I., Ritchie, K., Robine, J. M., Thijs, C., Tischer, C., Vellas, B., Zaidi, A., Alonso, F., Ranberg, K. Andersen, Andreeva, V., Ankri, J., Arnavielhe, S., Arshad, H., Auge, P., Berr, C., Bertone, P., Blain, H., Blasimme, A., Buijs, G. J., Caimmi, D., Carriazo, A., Cesario, A., Coletta, J., Cosco, T., Criton, M., Cuisinier, F., Demoly, P., Fernandez-Nocelo, S., Fougere, B., Garcia-Aymerich, J., Goldberg, M., Guldemond, N., Gutter, Z., Harman, D., Hendry, A., Heve, D., Illario, M., Jeandel, C., Krauss-Etschmann, S., Krys, O., Kula, D., Laune, D., Lehmann, S., Maier, D., Malva, J., Matignon, P., Melen, E., Mercier, G., Moda, G., Nizinkska, A., Nogues, M., O'Neill, M., Pelissier, J. Y., Poethig, D., Porta, D., Postma, D., Puisieux, F., Richards, M., Robalo-Cordeiro, C., Romano, V., Roubille, F., Schulz, H., Scott, A., Senesse, P., Slagter, S., Smit, H. A., Somekh, D., Stafford, M., Suanzes, J., Todo-Bom, A., Touchon, J., Traver-Salcedo, V., Van Beurden, M., Varraso, R., Vergara, I., Villalba-Mora, E., Wilson, N., Wouters, E., Zins, M., Bousquet, J., Kuh, D., Bewick, M., Standberg, T., Farrell, J., Pengelly, R., Joel, M. E., Rodriguez Manas, L., Mercier, J., Bringer, J., Camuzat, T., Bourret, R., Bedbrook, A., Kowalski, M. L., Samolinski, B., Bonini, S., Brayne, C., Michel, J. P., Venne, J., Viriot-Durandal, P., Alonso, J., Avignon, A., Ben-Shlomo, Y., Bousquet, P. J., Combe, B., Cooper, R., Hardy, R., Iaccarino, G., Keil, T., Kesse-Guyot, E., Momas, I., Ritchie, K., Robine, J. M., Thijs, C., Tischer, C., Vellas, B., Zaidi, A., Alonso, F., Ranberg, K. Andersen, Andreeva, V., Ankri, J., Arnavielhe, S., Arshad, H., Auge, P., Berr, C., Bertone, P., Blain, H., Blasimme, A., Buijs, G. J., Caimmi, D., Carriazo, A., Cesario, A., Coletta, J., Cosco, T., Criton, M., Cuisinier, F., Demoly, P., Fernandez-Nocelo, S., Fougere, B., Garcia-Aymerich, J., Goldberg, M., Guldemond, N., Gutter, Z., Harman, D., Hendry, A., Heve, D., Illario, M., Jeandel, C., Krauss-Etschmann, S., Krys, O., Kula, D., Laune, D., Lehmann, S., Maier, D., Malva, J., Matignon, P., Melen, E., Mercier, G., Moda, G., Nizinkska, A., Nogues, M., O'Neill, M., Pelissier, J. Y., Poethig, D., Porta, D., Postma, D., Puisieux, F., Richards, M., Robalo-Cordeiro, C., Romano, V., Roubille, F., Schulz, H., Scott, A., Senesse, P., Slagter, S., Smit, H. A., Somekh, D., Stafford, M., Suanzes, J., Todo-Bom, A., Touchon, J., Traver-Salcedo, V., Van Beurden, M., Varraso, R., Vergara, I., Villalba-Mora, E., Wilson, N., Wouters, E., and Zins, M.

Published
2015

7. Operational definition of Active and Healthy Ageing (AHA): A conceptual framework

Author

Cardiometabolic Health, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Bousquet, J., Kuh, D., Bewick, M., Standberg, T., Farrell, J., Pengelly, R., Joel, M. E., Rodriguez Manas, L., Mercier, J., Bringer, J., Camuzat, T., Bourret, R., Bedbrook, A., Kowalski, M. L., Samolinski, B., Bonini, S., Brayne, C., Michel, J. P., Venne, J., Viriot-Durandal, P., Alonso, J., Avignon, A., Ben-Shlomo, Y., Bousquet, P. J., Combe, B., Cooper, R., Hardy, R., Iaccarino, G., Keil, T., Kesse-Guyot, E., Momas, I., Ritchie, K., Robine, J. M., Thijs, C., Tischer, C., Vellas, B., Zaidi, A., Alonso, F., Ranberg, K. Andersen, Andreeva, V., Ankri, J., Arnavielhe, S., Arshad, H., Auge, P., Berr, C., Bertone, P., Blain, H., Blasimme, A., Buijs, G. J., Caimmi, D., Carriazo, A., Cesario, A., Coletta, J., Cosco, T., Criton, M., Cuisinier, F., Demoly, P., Fernandez-Nocelo, S., Fougere, B., Garcia-Aymerich, J., Goldberg, M., Guldemond, N., Gutter, Z., Harman, D., Hendry, A., Heve, D., Illario, M., Jeandel, C., Krauss-Etschmann, S., Krys, O., Kula, D., Laune, D., Lehmann, S., Maier, D., Malva, J., Matignon, P., Melen, E., Mercier, G., Moda, G., Nizinkska, A., Nogues, M., O'Neill, M., Pelissier, J. Y., Poethig, D., Porta, D., Postma, D., Puisieux, F., Richards, M., Robalo-Cordeiro, C., Romano, V., Roubille, F., Schulz, H., Scott, A., Senesse, P., Slagter, S., Smit, H. A., Somekh, D., Stafford, M., Suanzes, J., Todo-Bom, A., Touchon, J., Traver-Salcedo, V., Van Beurden, M., Varraso, R., Vergara, I., Villalba-Mora, E., Wilson, N., Wouters, E., Zins, M., Cardiometabolic Health, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Bousquet, J., Kuh, D., Bewick, M., Standberg, T., Farrell, J., Pengelly, R., Joel, M. E., Rodriguez Manas, L., Mercier, J., Bringer, J., Camuzat, T., Bourret, R., Bedbrook, A., Kowalski, M. L., Samolinski, B., Bonini, S., Brayne, C., Michel, J. P., Venne, J., Viriot-Durandal, P., Alonso, J., Avignon, A., Ben-Shlomo, Y., Bousquet, P. J., Combe, B., Cooper, R., Hardy, R., Iaccarino, G., Keil, T., Kesse-Guyot, E., Momas, I., Ritchie, K., Robine, J. M., Thijs, C., Tischer, C., Vellas, B., Zaidi, A., Alonso, F., Ranberg, K. Andersen, Andreeva, V., Ankri, J., Arnavielhe, S., Arshad, H., Auge, P., Berr, C., Bertone, P., Blain, H., Blasimme, A., Buijs, G. J., Caimmi, D., Carriazo, A., Cesario, A., Coletta, J., Cosco, T., Criton, M., Cuisinier, F., Demoly, P., Fernandez-Nocelo, S., Fougere, B., Garcia-Aymerich, J., Goldberg, M., Guldemond, N., Gutter, Z., Harman, D., Hendry, A., Heve, D., Illario, M., Jeandel, C., Krauss-Etschmann, S., Krys, O., Kula, D., Laune, D., Lehmann, S., Maier, D., Malva, J., Matignon, P., Melen, E., Mercier, G., Moda, G., Nizinkska, A., Nogues, M., O'Neill, M., Pelissier, J. Y., Poethig, D., Porta, D., Postma, D., Puisieux, F., Richards, M., Robalo-Cordeiro, C., Romano, V., Roubille, F., Schulz, H., Scott, A., Senesse, P., Slagter, S., Smit, H. A., Somekh, D., Stafford, M., Suanzes, J., Todo-Bom, A., Touchon, J., Traver-Salcedo, V., Van Beurden, M., Varraso, R., Vergara, I., Villalba-Mora, E., Wilson, N., Wouters, E., and Zins, M.

Published
2015

8. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer

Author

Ho-Pun-Cheung, A, primary, Assenat, E, additional, Bascoul-Mollevi, C, additional, Bibeau, F, additional, Boissière-Michot, F, additional, Thezenas, S, additional, Cellier, D, additional, Azria, D, additional, Rouanet, P, additional, Senesse, P, additional, Ychou, M, additional, and Lopez-Crapez, E, additional

Published
2010
Full Text
View/download PDF

9. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres

Author

Pressoir, M, primary, Desné, S, additional, Berchery, D, additional, Rossignol, G, additional, Poiree, B, additional, Meslier, M, additional, Traversier, S, additional, Vittot, M, additional, Simon, M, additional, Gekiere, J P, additional, Meuric, J, additional, Serot, F, additional, Falewee, M N, additional, Rodrigues, I, additional, Senesse, P, additional, Vasson, M P, additional, Chelle, F, additional, Maget, B, additional, Antoun, S, additional, and Bachmann, P, additional

Published
2010
Full Text
View/download PDF

10. Letter to the Editor.

Author

Pahlman, L, Rouanet, P, Saint-Aubert, B, Lemanski, C, Senesse, P, Gourgou, S, Quenet, F, Ychou, M, Kramar, A, Dubois, J, Pahlman, L, Rouanet, P, Saint-Aubert, B, Lemanski, C, Senesse, P, Gourgou, S, Quenet, F, Ychou, M, Kramar, A, and Dubois, J

Published
2002

14. Summary version of the Standards, Options and Recommendations for palliative or terminal nutrition in adults with progressive cancer (2001)

Author

Bachmann, P, primary, Marti-Massoud, C, additional, Blanc-Vincent, M P, additional, Desport, J C, additional, Colomb, V, additional, Dieu, L, additional, Kere, D, additional, Melchior, J C, additional, Nitenberg, G, additional, Raynard, B, additional, Roux-Bournay, P, additional, Schneider, S, additional, and Senesse, P, additional

Published
2003
Full Text
View/download PDF

21. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer

Author

Ychou Marc, Rouanet Philippe, Lemanski Claire, Zouhair Abderrahim, Barbier Nicolas, Bibeau Frederic, Azria David, Senesse Pierre, Ozsahin Mahmut, Pèlegrin André, Dubois Jean-Bernard, and Thèzenas Simon

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Epidermal growth factor receptor (EGFR) represents a major target for current radiosensitizing strategies. We wished to ascertain whether a correlation exists between the expression of EGFR and treatment outcome in a group of patients with rectal adenocarcinoma who had undergone preoperative radiotherapy (RT). Methods Within a six-year period, 138 patients underwent preoperative radiotherapy and curative surgery for rectal cancer (UICC stages II-III) at our institute. Among them, 77 pretherapeutic tumor biopsies were available for semi-quantitative immunohistochemical investigation evaluating the intensity and the number (extent) of tumor stained cells. Statistical analyses included Cox regression for calculating risk ratios of survival endpoints and logistic regression for determining odds ratios for the development of loco-regional recurrences. Results Median age was 64 years (range: 30–88). Initial staging showed 75% and 25% stage II and III tumors, respectively. RT consisted of 44-Gy pelvic irradiation in 2-Gy fractions using 18-MV photons. In 25 very low-rectal-cancer patients the primary tumor received a boost dose of up to 16 Gy for a sphincter-preservation approach. Concomitant chemotherapy was used in 17% of the cases. All patients underwent complete total mesorectal resection. Positive staining (EGFR+) was observed in 43 patients (56%). Median follow-up was 36 months (range: 6–86). Locoregional recurrence rates were 7 and 20% for EGFR extent inferior and superior to 25%, respectively. The corresponding locoregional recurrence-free survival rate at two years was 94% (95% confidence interval, CI, 92–98%) and 84% (CI 95%, 58–95%), respectively (P = 0.06). Multivariate analyses showed a significant correlation between the rate of loco-regional recurrence and three parameters: EGFR extent superior to 25% (hazard ratio = 7.18, CI 95%, 1.17–46, P = 0.037), rectal resection with microscopic residue (hazard ratio = 6.92, CI 95%, 1.18–40.41, P = 0.032), and a total dose of 44 Gy (hazard ratio = 5.78, CI 95%, 1.04–32.05, P = 0.045). Conclusion EGFR expression impacts on loco-regional recurrence. Knowledge of expression of EGFR in rectal cancer could contribute to the identification of patients with an increased risk of recurrences, and to the prediction of prognosis.

Published
2005
Full Text
View/download PDF

22. Summary of the Standards, Options and Recommendations for nutritional support in patients undergoing bone marrow transplantation (2002).

Author

Raynhard, B, Nitenberg, G, Gory-Delabaere, G, Bourhis, JH, Bachmann, P, Bensadoun, RJ, Desport, JC, Kere, D, Schneider, S, Senesse, P, Bordigoni, P, and Dieu, L

Subjects
BONE marrow transplantation, MALNUTRITION, BONE marrow, NUTRITION disorders, IMMUNE system
Abstract

Presents guidelines of the organizing committee Standards, Options and Recommendations for nutritional support in patients undergoing bone marrow transplantation. Role of enteral and parenteral nutrition in the nutritional management of patients who have undergone or who will undergo bone marrow transplantation; Risk during bone marrow transplantation; Clinical and metabolic consequences of malnutrition

Published
2003
Full Text
View/download PDF

23. Operational definition of Active and Healthy Ageing (AHA)

Author

Henriette A. Smit, Neil Wilson, Jean-Marie Robine, J. Y. Pelissier, M. Van Beurden, A. Bedbrook, T. Standberg, Vittorio Romano, Bertrand Fougère, J. Garcia-Aymerich, C. Jeandel, Anne Hendry, B. Samolinski, Mike Bewick, Holger Schulz, P. Bertone, Yoav Ben-Shlomo, J. Coletta, D. Poethig, J. P. Michel, Valentina A. Andreeva, M. O'Neill, M. Nogues, K. Andersen Ranberg, Elena Villalba-Mora, Daniel Laune, Itziar Vergara, Maddalena Illario, F. Roubille, G. J. Buijs, J. Venne, Sylvie Arnavielhe, L. Rodriguez Manas, Carol Brayne, David Somekh, T. Camuzat, Jacques Bringer, A. Nizinkska, Marcel Goldberg, Carel Thijs, Alessandro Blasimme, Raphaëlle Varraso, Dieter Maier, Marie Zins, D. Heve, François Puisieux, Theodore D. Cosco, D. Harman, João O. Malva, Thomas Keil, Rachel Cooper, J. Mercier, M. Criton, Alfredo Cesario, Philippe-Jean Bousquet, Jean Bousquet, Davide Caimmi, John Farrell, Emmanuelle Kesse-Guyot, Dirkje S. Postma, Karen Ritchie, Joël Ankri, P. Viriot-Durandal, Pascal Demoly, G. Moda, V. Traver-Salcedo, Susanne Krauss-Etschmann, Daniela Porta, D. Kula, Jordi Alonso, Federico Alonso, Ana Todo-Bom, Frédéric Cuisinier, R. Pengelly, Guido Iaccarino, G. Mercier, C. Robalo-Cordeiro, Eveline Wouters, P. Senesse, P. Matignon, J. Touchon, Sergio Bonini, B. Combe, J. Suanzes, Marek L. Kowalski, A. Zaidi, Isabelle Momas, R. Bourret, Hasan Arshad, A. Avignon, Sylvain Lehmann, Ana Maria Carriazo, Diana Kuh, Claudine Berr, Mai Stafford, A. Scott, Marcus Richards, S. Fernandez-Nocelo, Rebecca Hardy, Z. Gutter, M. E. Joel, Erik Melén, C. Tischer, Sandra N. Slagter, Nick A. Guldemond, Bruno Vellas, H. Blain, P. Auge, O. Krys, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Institut d'Electronique du Solide et des Systèmes (InESS), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Departamento de Biología Molecular y Celular del Cáncer (CSIC-UAM), Instituto de Investigaciones Biomédicas A. Sols, Hôpital Lapeyronie [Montpellier] (CHU), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Mécanismes moléculaires dans les démences neurodégénératives (MMDN), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Gérontopôle, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse], Université Paris-Est Marne-la-Vallée (UPEM), Université de Montpellier (UM), Euromov (EuroMov), Eindhoven University of Technology [Eindhoven] (TU/e), Laboratoire de Bioingénierie et NanoSciences (LBN), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, IMIM-Hospital del Mar, Generalitat de Catalunya, Groupe Matrice Extracellulaire et Biomineralisation, Université Paris Descartes - Paris 5 (UPD5), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Julius Center for Health Sciences and Primary Care, University Medical Center [Utrecht], Service de Pneumologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cohortes épidémiologiques en population (CONSTANCES), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Paris (UP), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon ( MACVIA-LR ), Université Montpellier 1 ( UM1 ) -World Health Organization ( WHO/OMS ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ) -European Innovation Partnership on Active and Healthy Ageing Reference Site, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] ( PhyMedExp ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de pharmacologie et innovation dans le diabète ( CPID ), Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Centre National de la Recherche Scientifique ( CNRS ), Medical University of Warsaw-Faculté de Pharmacie de Paris, CNR, Rome, Italy and Department of Medicine-Second University of Naples, Institut d'Electronique du Solide et des Systèmes ( InESS ), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique ( CNRS ), Departamento de Biología Molecular y Celular del Cáncer ( CSIC-UAM ), Hôpital Lapeyronie [Montpellier] ( CHU ), Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle ( CRESS - U1153 ), Université Paris 13 ( UP13 ) -Institut National de la Recherche Agronomique ( INRA ) -Conservatoire National des Arts et Métiers [CNAM] ( CNAM ) -Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ), Gerontopole of Toulouse, CHU- Université de Toulouse, Université Paris-Est Marne-la-Vallée ( UPEM ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Eindhoven University of Technology [Eindhoven] ( TU/e ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Arnaud de Villeneuve, Université Paris Descartes - Paris 5 ( UPD5 ), Institut de Recherche en Infectiologie de Montpellier ( IRIM ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ), Institut de génétique humaine ( IGH ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire AIM, Université Paris Diderot - Paris 7 ( UPD7 ) -Centre d'Etudes de Saclay, Telecom Bretagne, Brest, Laboratoire de magnétisme et d'optique de Versailles ( LMOV ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Centre National de la Recherche Scientifique ( CNRS ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Departement de Cardiologie, Space Science Division, Neuropsychiatrie : recherche épidémiologique et clinique, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Montpellier 1 ( UM1 ) -Université de Montpellier ( UM ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Antoine Béclère, UMS11 Cohortes en population, Institut National de la Santé et de la Recherche Médicale ( INSERM ), Bousquet, J, Kuh, D, Bewick, M, Standberg, T, Farrell, J, Pengelly, R, Joel, M. E, Rodriguez Mañas, L, Mercier, J, Bringer, J, Camuzat, T, Bourret, R, Bedbrook, A, Kowalski, M. L, Samolinski, B, Bonini, S, Brayne, C, Michel, J. P, Venne, J, Viriot Durandal, P, Alonso, J, Avignon, A, Ben Shlomo, Y, Bousquet, P. J, Combe, B, Cooper, R, Hardy, R, Iaccarino, G, Keil, T, Kesse Guyot, E, Momas, I, Ritchie, K, Robine, J. M, Thijs, C, Tischer, C, Vellas, B, Zaidi, A, Alonso, F, Andersen Ranberg, K, Andreeva, V, Ankri, J, Arnavielhe, S, Arshad, H, Augé, P, Berr, C, Bertone, P, Blain, H, Blasimme, A, Buijs, G. J, Caimmi, D, Carriazo, A, Cesario, A, Coletta, J, Cosco, T, Criton, M, Cuisinier, F, Demoly, P, Fernandez Nocelo, S, Fougère, B, Garcia Aymerich, J, Goldberg, M, Guldemond, N, Gutter, Z, Harman, D, Hendry, A, Heve, D, Illario, Maddalena, Jeandel, C, Krauss Etschmann, S, Krys, O, Kula, D, Laune, D, Lehmann, S, Maier, D, Malva, J, Matignon, P, Melen, E, Mercier, G, Moda, G, Nizinkska, A, Nogues, M, O'Neill, M, Pelissier, J. Y, Poethig, D, Porta, D, Postma, D, Puisieux, F, Richards, M, Robalo Cordeiro, C, Romano, V, Roubille, F, Schulz, H, Scott, A, Senesse, P, Slagter, S, Smit, H. A, Somekh, D, Stafford, M, Suanzes, J, Todo Bom, A, Touchon, J, Traver Salcedo, V, Van Beurden, M, Varraso, R, Vergara, I, Villalba Mora, E, Wilson, N, Wouters, E, Zins, M., CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), École Pratique des Hautes Études (EPHE), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPCité), Bousquet, Jean, Kuh, D., Bewick, M., Standberg, T., Farrell, J., Pengelly, R., Joel, M. E., Rodriguez Mañas, L., Mercier, J., Bringer, J., Camuzat, T., Bourret, R., Bedbrook, A., Kowalski, M. L., Samolinski, B., Bonini, Sergio, Brayne, C., Michel, J. P., Venne, J., Viriot Durandal, P., Alonso, J., Avignon, A., Ben Shlomo, Y., Bousquet, P. J., Combe, B., Cooper, R., Hardy, R., Iaccarino, G., Keil, T., Kesse Guyot, E., Momas, I., Ritchie, K., Robine, J. M., Thijs, C., Tischer, C., Vellas, B., Zaidi, A., Alonso, F., Andersen Ranberg, K., Andreeva, V., Ankri, J., Arnavielhe, S., Arshad, H., Augé, P., Berr, C., Bertone, P., Blain, H., Blasimme, A., Buijs, G. J., Caimmi, D., Carriazo, A., Cesario, A., Coletta, J., Cosco, T., Criton, M., Cuisinier, F., Demoly, P., Fernandez Nocelo, S., Fougère, B., Garcia Aymerich, J., Goldberg, M., Guldemond, N., Gutter, Z., Harman, D., Hendry, A., Heve, D., Illario, M., Jeande, C., Krauss Etschmann, S., Krys, O., Kula, D., Laune, D., Lehmann, S., Maier, D., Malva, J., Matignon, P., Melen, E., Mercier, G., Moda, G., Nizinkska, A., Nogues, M., O’Neill, M., Pelissier, J. Y., Poethig, D., Porta, D., Postma, D., Puisieux, F., Richards, M., Robalo Cordeiro, C., Romano, V., Roubille, F., Schulz, H., Scott, A., Senesse, P., Slagter, S., Smit, H. A., Somekh, D., Stafford, M., Suanzes, J., Todo Bom, A., Touchon, J., Traver Salcedo, V., Van Beurden, M., Varraso, R., Vergara, I., Villalba Mora, E., Wilson, N., Wouters, E., Groningen Research Institute for Asthma and COPD (GRIAC), Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, RS: CAPHRI - R5 - Optimising Patient Care, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Montpellier (UM)-École pratique des hautes études (EPHE), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, UMS011 Cohortes épidémiologiques en population (CONSTANCES), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Gerontology, Aging, media_common.quotation_subject, [SDV]Life Sciences [q-bio], EUROPEAN INNOVATION PARTNERSHIP, Population, Medicine (miscellaneous), Social Environment, MACVIA-LR, Quality of life (healthcare), European Innovation Partnership on Active and Healthy Ageing, Active and Healthy Ageing, PREVENTING CHRONIC DISEASES, definition, Nutrition and Dietetics, Geriatrics and Gerontology, LIFE YEARS, Nutrition and Dietetic, Journal Article, Medicine, Humans, DISEASES CHRONIC DISEASES, Function (engineering), education, Exercise, ComputingMilieux_MISCELLANEOUS, POPULATION, media_common, education.field_of_study, [ SDV ] Life Sciences [q-bio], business.industry, Operational definition, EIP, Social environment, Conceptual framework, Health, General partnership, Chronic Disease, Quality of Life, France, Independent Living, business, Independent living, Human, macvia lr
Abstract

Health is a multi-dimensional concept, capturing how people feel and function. The broad concept of Active and Healthy Ageing was proposed by the World Health Organisation (WHO) as the process of optimizing opportunities for health to enhance quality of life as people age. It applies to both individuals and population groups. A universal Active and Healthy Ageing definition is not available and it may differ depending on the purpose of the definition and/or the questions raised. While the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) has had a major impact, a definition of Active and Healthy Ageing is urgently needed. A meeting was organised in Montpellier, France, October 20-21, 2014 as the annual conference of the EIP on AHA Reference Site MACVIA-LR (Contre les Maladies Chroniques pour un Vieillissement Actif en Languedoc Roussillon) to propose an operational definition of Active and Healthy Ageing including tools that may be used for this. The current paper describes the rationale and the process by which the aims of the meeting will be reached. Health is a multi-dimensional concept, capturing how people feel and function. The broad concept of Active and Healthy Ageing was proposed by the World Health Organisation (WHO) as the process of optimizing opportunities for health to enhance quality of life as people age. It applies to both individuals and population groups. A universal Active and Healthy Ageing definition is not available and it may differ depending on the purpose of the definition and/or the questions raised. While the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) has had a major impact, a definition of Active and Healthy Ageing is urgently needed. A meeting was organised in Montpellier, France, October 20-21, 2014 as the annual conference of the EIP on AHA Reference Site MACVIA-LR (Contre les Maladies Chroniques pour un Vieillissement Actif en Languedoc Roussillon) to propose an operational definition of Active and Healthy Ageing including tools that may be used for this. The current paper describes the rationale and the process by which the aims of the meeting will be reached.

Published
2015
Full Text
View/download PDF

24. Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy.

Author

Assenat E, Thezenas S, Flori N, Pere-Charlier N, Garrel R, Serre A, Azria D, and Senesse P

Abstract

CONTEXT: Few studies have evaluated outcomes of combined chemoradiotherapy for Stage III-IV head and neck squamous cell carcinoma in terms of the use of nutritional support by means of percutaneous endoscopic gastrostomy (PEG). OBJECTIVES: To compare nutritional status and treatment interruption because of acute toxicity in patients with advanced head and neck tumors who were treated by combined chemoradiotherapy and received or did not receive prophylactic PEG tubes. METHODS: This was a retrospective study that evaluated data obtained from a cancer center in Montpellier, France. A total of 139 consecutive patients treated for Stage III-IV head and neck squamous cell carcinoma from January 1, 1998 to June 30, 2003 were evaluated in terms of nutritional status before and after therapy, treatment interruption because of toxicity, and duration of hospitalization. RESULTS: Seventy-eight of the 139 patients (58%) did not receive prophylactic PEG feeding, and 61 patients (44%) received PEG feeding. Pretreatment nutritional status was worse in the PEG group. Compared with the initial nutritional status, nutritional status at the end of treatment was unchanged in the PEG group and much worse in the group that did not receive the PEG (P<0.05). Cumulative incidence of treatment interruption because of toxicity was significantly lower in the PEG group than in the no-PEG group (100 and 236 days of interruption, respectively, P=0.03) and hospitalization was significantly shorter (P=0.003). CONCLUSION: Prophylactic PEG sustains nutritional status and reduces the cumulative incidence of treatment interruption caused by toxicity and duration of hospitalization. A randomized study is warranted to validate these results. [ABSTRACT FROM AUTHOR]

Published
2011

25. Operational Definition of Active and Healthy Aging (AHA): The European Innovation Partnership (EIP) on AHA Reference Site Questionnaire: Montpellier October 20-21, 2014, Lisbon July 2, 2015

Author

Karen Ritchie, Daniel Harman, Philippe-Jean Bousquet, Erik Melén, Pierre Senesse, Govert Joan Buijs, Antonio Cano, Claude Jeandel, Timo E. Strandberg, Marieke Van Beurden, Pascal Demoly, G. Moda, Raquel Santiago, Sylvie Arnavielhe, Marie-Eve Joel, Nicola Wilson, Eveline Wouters, Jacques Touchon, Martina O'Neill, Isabelle Momas, Karen Andersen Ranberg, D. Heve, Maddalena Illario, Christina Tischer, Jean Bousquet, Marcel Goldberg, Paola Bertone, Guido Iaccarino, Antoine Avignon, Rodolphe Bourret, Valeria Romano, Laura Calzà, Henriet A. Smit, Mirca Barbolini, David Kula, Jacques-Yves Pelissier, Mario Barbagallo, Bruno Vellas, Ann Scott, C. Robalo-Cordeiro, Gregoire Mercier, Mike Bewick, Bernard Combe, Holger Schulz, Sergio Bonini, P. Viriot-Durandal, Itziar Vergara, M. Nogues, Carol Brayne, João Apóstolo, Jacques Mercier, Vicente Traver-Salcedo, François Puisieux, Julia Coletta, Alessandro Blasimme, Olivier Krys, Niels H. Chavannes, John Farrell, Joël Ankri, Ana Maria Carriazo, Rafaelle Varraso, Marie Zins, Zdenec Gutter, José António Pereira da Silva, Bertrand Fougère, Frédéric Cuisinier, Bolesław Samoliński, Jacques Bringer, Theodore D. Cosco, Jordi Alonso, Ana Todo-Bom, Claudine Berr, Daniel Laune, Esteban De Manuel Keenoy, Judith Garcia-Aymerich, Anna Bedbrook, Anne Hendry, Richard Pengelly, Dagmar Poethig, João O. Malva, Thomas Keil, Sandra N. Slagter, Nick A. Guldemond, Pierre Matignon, Hubert Blain, Leocadio Rodríguez Mañas, Marek L. Kowalski, Susana Fernandez-Nocelo, Alfredo Cesario, Sandra Rebello, Federico Alonso, Catarina R. Oliveira, Dieter Maier, Jean-Pierre Michel, David Somekh, T. Camuzat, Julien Venne, Marc Criton, Jaime Correia de Sousa, Hassan Arshad, Anabella Mota Pinto, Valentina A. Andreeva, François Roubille, Yoav Ben-Shlomo, Asghar Zaidi, Elena Villalba-Mora, Emmanuelle Kesse-Guyot, Dirkje S. Postma, Carel Thijs, Jean-Marie Robine, Danielle Porta, George Crooks, Adrianna Nizinska, Jorge Suanzes, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Bone and Joint Research Group, University of Southampton Medical School, CHU Toulouse [Toulouse], Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Santé publique et épidémiologie des déterminants professionnels et sociaux de la santé, Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department of Social Medicine, University of Bristol [Bristol], Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-IFR76-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Electrical Engineering, Mathematics and Computer Science [Delft], Delft University of Technology (TU Delft), Unité de Recherche en Epidémiologie Nutritionnelle (UREN), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), F2ME, PSA Peugeot - Citroën (PSA), PSA Peugeot Citroën (PSA)-PSA Peugeot Citroën (PSA)-Laboratoire Pluridisciplinaire de Recherche en Ingénierie des Systèmes, Mécanique et Energétique (PRISME), Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges), Department of Epidemiology and Public Health, Imperial College London, CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-École des hautes études en sciences sociales (EHESS), Département Ecologie, Physiologie et Ethologie (DEPE-IPHC), Institut Pluridisciplinaire Hubert Curien (IPHC), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS)-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw - Poland, Department of Epidemiology, Maastricht University [Maastricht]-School for Public Health and Primary Care (CAPHRI), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Kyomed, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Geriatrics - Efficiency and Deficiency Laboratory, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Consiglio Nazionale delle Ricerche (CNR), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Department of Public Health and Primary Care, University of Cambridge [UK] (CAM), Service d'endocrinologie, Departamento de Sistemas Informáticos y Computación [Valencia], Universitat Politècnica de València (UPV), Deputy Scientific Director, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Laboratoire de chimie biomoléculaire (LCB), Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-MAYOLI SPINDLER SA-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Bioingénierie et NanoSciences (LBN), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Laboratoire de Gérontechnologie [Hôpital La Grave-CHU de Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Gérontopôle, IMIM-Hospital del Mar, Generalitat de Catalunya, Département de Biostatistiques, Agence Régionale de Santé Languedoc Roussillon (ARS), Department of Medicine and Surgery, Università degli Studi di Salerno (UNISA)-RCCS 'Multimedia', Centre de gérontologie clinique, Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Lab-STICC_TB_CID_TOMS, Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA), Unité de Virologie clinique et fondamentale (UVCF), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Mécanismes adaptatifs : des organismes aux communautés (MAOAC), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Department of Pulmonary Medicine and Tuberculosis, University of Groningen [Groningen], Service de gériatrie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Allergy and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Département de nutrition et d'oncologie digestive, CRLCC Val d'Aurelle - Paul Lamarque, Institute of Epidemiology [Neuherberg] (EPI), German Research Center for Environmental Health - Helmholtz Center München (GmbH), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Bousquet, Jean, Malva, Joao, Nogues, Michel, Mañas, Leocadio Rodriguez, Vellas, Bruno, Farrell, J, Bewick, M, Kowalski, Ml, Strandberg, T, Alonso, J, Ranberg, Ka, Ankri, J, Barbagallo, M, Ben Shlomo, Y, Berr, C, Crooks, G, de Manuel Keenoy, E, Goldberg, M, Guldemond, N, Illario, Maddalena, Joel, Me, Kesse Guyot, E, Michel, Jp, Pengelly, R, Ritchie, K, Robine, Jm, Romano, V, Samolinski, B, Schulz, H, Thijs, C, Touchon, J, Zaidi, A, Apostolo, J, Alonso, F, Andreeva, V, Arnavielhe, S, Arshad, H, Avignon, A, Barbolini, M, Bedbrook, A, Bertone, P, Blain, H, Blasimme, A, Bonini, S, Bourret, R, Bousquet, Pj, Brayne, C, Bringer, J, Buijs, Gj, Calza, L, Camuzat, T, Cano, A, Carriazo, A, Cesario, A, Chavannes, N, Combe, B, Coletta, J, de Sousa, Jc, Cosco, T, Criton, M, Cuisinier, F, Demoly, P, Fernandez Nocelo, S, Fougère, B, Garcia Aymerich, J, Gutter, Z, Harman, D, Hendry, A, Hève, D, Iaccarino, G, Jeandel, C, Keil, T, Krys, O, Kula, D, Laune, D, Maier, D, Matignon, P, Melen, E, Mercier, G, Moda, G, Momas, I, Pinto, Am, Nizinska, A, Oliveira, C, O'Neill, M, Pelissier, Jy, Pereira da Silva, Ja, Poethig, D, Porta, D, Postma, D, Puisieux, F, Rebello, S, Robalo Cordeiro, C, Roubille, F, Santiago, R, Scott, A, Senesse, P, Slagter, S, Smit, Ha, Somekh, D, Suanzes, J, Tischer, C, Todo Bom, A, Traver Salcedo, V, Van Beurden, M, Varraso, R, Venne, J, Vergara, I, Villalba Mora, E, Viriot Durandal, P, Wilson, N, Wouters, E, Zins, M, Mercier, J., Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Cité (USPC)-Université Paris 13 (UP13)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut National de la Recherche Agronomique (INRA), Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHU Montpellier, Universidad Politécnica de Valencia, Centre National de la Recherche Scientifique (CNRS)-MAYOLI SPINDLER SA-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Université Montpellier 2 - Sciences et Techniques (UM2), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Gérontopôle-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse], University of Salerno (UNISA)-RCCS 'Multimedia', Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin -Epidemiology and Health Economics, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Universidad Pública de Navarra [Espagne] (UPNA), Unité de Virologie clinique et fondamentale EA 4294, Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF)-Muséum national d'Histoire naturelle (MNHN), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Bousquet J, Malva J, Nogues M, Mañas LR, Vellas B, Farrell J, MACVIA Research Group [.., L. Calzà, ], Farrell, John, Bonini, Sergio, Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Muséum national d'Histoire naturelle (MNHN)-Collège de France (CdF)-Centre National de la Recherche Scientifique (CNRS), Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, and RS: CAPHRI - R5 - Optimising Patient Care

Subjects
Gerontology, Concept Formation, [SDV]Life Sciences [q-bio], Disability Evaluation, 0302 clinical medicine, SF-12, QUALITY-OF-LIFE, Surveys and Questionnaires, WHODAS 2.0, Medicine, 030212 general & internal medicine, VERSION, POPULATION, PSYCHOLOGICAL DISTRESS, SCALE, General Nursing, Nursing (all)2901 Nursing (miscellaneous), health care economics and organizations, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, education.field_of_study, Operational definition, Medicine (all), Health Policy, PHYSICAL-ACTIVITY QUESTIONNAIRE, PRIMARY-CARE, General Medicine, 3. Good health, Europe, General partnership, Scale (social sciences), Population, SELF-REPORT, VALIDATION, 03 medical and health sciences, Quality of life (healthcare), EQ-5D, Journal Article, Humans, OLDER-ADULTS, education, Geriatric Assessment, Health policy, Aged, business.industry, questionnaire, Active and healthy ageing, United States, Questionnaire, Quality of Life, The Conceptual Framework, Geriatrics and Gerontology, business, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

A core operational definition of active and healthy aging (AHA) is needed to conduct comparisons. A conceptual AHA framework proposed by the European Innovation Partnership on Active and Healthy Ageing Reference Site Network includes several items such as functioning (individual capability and underlying body systems), well-being, activities and participation, and diseases (including non-communicable diseases, frailty, mental and oral health disorders). The instruments proposed to assess the conceptual framework of AHA have common applicability and availability attributes. The approach includes core and optional domains/instruments depending on the needs and the questions. A major common domain is function, as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). WHODAS 2.0 can be used across all diseases and healthy individuals. It covers many of the AHA dimensions proposed by the Reference Site network. However, WHODAS 2.0 does not include all dimensions proposed for AHA assessment. The second common domain is health-related quality of life (HRQoL). A report of the AHA questionnaire in the form of a spider net has been proposed to facilitate usual comparisons across individuals and groups of interest. (C) 2015 Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Published
2015
Full Text
View/download PDF

26. Identification of 18 F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer.

Author

Galvez T, Berkane I, Thézenas S, Eberlé MC, Flori N, Guillemard S, Ilonca AD, Santoro L, Kotzki PO, Senesse P, and Deshayes E

Subjects
Humans, Fluorodeoxyglucose F18, Retrospective Studies, Prognosis, Weight Loss, Tumor Burden, Glycolysis, Positron Emission Tomography Computed Tomography, Esophageal Neoplasms diagnostic imaging
Abstract

18 F-FDG PET-CT is routinely performed as part of the initial staging of numerous cancers. Other than having descriptive, predictive and prognostic values for tumors, 18 F-FDG PET-CT provides full-body data, which could inform on concurrent pathophysiological processes such as malnutrition. To test this hypothesis, we measured the 18 F-FDG uptake in several organs and evaluated their association with weight loss in patients at diagnosis of esophageal cancer. Forty-eight patients were included in this retrospective monocentric study. 18 F-FDG uptake quantification was performed in the brain, the liver, the spleen, bone marrow, muscle and the esophageal tumor itself and was compared between patients with different amounts of weight loss. We found that Total Lesion Glycolysis (TLG) and peak Standardized Uptake Values (SUV peak ) measured in the brain correlated with the amount of weight loss: TLG was, on average, higher in patients who had lost more than 5% of their usual weight, whereas brain SUV peak were, on average, lower in patients who had lost more than 10% of their weight. Higher TLG and lower brain SUV peak were associated with worse OS in the univariate analysis. This study reports a new and significant association between 18 F-FDG uptake in the brain and initial weight loss in patients with esophageal cancer.

Published
2023
Full Text
View/download PDF

27. Trismus Occurrence and Link With Radiotherapy Doses in Head and Neck Cancer Patients Treated With Chemoradiotherapy.

Author

Faravel K, Jarlier M, Senesse P, Huteau ME, Janiszewski C, Stoebner A, and Boisselier P

Subjects
Humans, Male, Adult, Middle Aged, Aged, Female, Trismus epidemiology, Trismus etiology, Quality of Life, Chemoradiotherapy adverse effects, Head and Neck Neoplasms therapy, Carcinoma, Squamous Cell
Abstract

Background: Chemoradiotherapy (CRT) for head and neck cancer (HNC) induces side-effects, including trismus, which impairs quality of life by causing difficulty to eat, speak, and maintain good oral hygiene, and by altering social life. Given the wide variation of reported trismus prevalence and as a first mandatory step for the preventive physiotherapy OPEN program (NCT03979924) this study evaluated trismus occurrence and its link with radiation doses., Methods: Study population was non-larynx HNC patients with epidermoid carcinoma treated with CRT, with or without surgery. A physiotherapist measured maximal interincisal distance before, during and after CRT, at 10 weeks and 6 months. The proportion of patients with trismus (with a 95% confidence interval) was estimated. Irradiation doses were analyzed between patients with and without trismus using non-parametric Kruskal-Wallis test., Results: We included 45 patients (77.8% male), median age 61 years (range 41-77). The proportion of trismus at baseline was 24.4%, 26.8% at 10 weeks and 37.1% at 6 months. During radiotherapy, it was 27.9% at week 3 and increased to 41.9% at week 6. Trismus occurrence at 10 weeks was higher when the radiation dose to the ipsilateral lateral pterygoid muscle was above the median value, that is, 36.8 grays., Conclusion: Trismus occurrence differed according to radiation dose and cancer location. These findings highlight the necessity of early preventive physiotherapy programs to reduce trismus occurrence. The second step, of the interventional multicenter OPEN program, is currently evaluating the impact of preventive physiotherapy and patient education on trismus in a sample of 175 patients.

Published
2023
Full Text
View/download PDF

29. Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis.

Author

Martin L, Muscaritoli M, Bourdel-Marchasson I, Kubrak C, Laird B, Gagnon B, Chasen M, Gioulbasanis I, Wallengren O, Voss AC, Goldwasser F, Jagoe RT, Deans C, Bozzetti F, Strasser F, Thoresen L, Kazemi S, Baracos V, and Senesse P

Subjects
Canada, Cohort Studies, Eating, Humans, Inflammation diagnosis, Weight Loss, Cachexia diagnosis, Cachexia etiology, Neoplasms complications, Neoplasms diagnosis, Neoplasms epidemiology
Abstract

Background: Cancer-associated weight loss (WL) associates with increased mortality. International consensus suggests that WL is driven by a variable combination of reduced food intake and/or altered metabolism, the latter often represented by the inflammatory biomarker C-reactive protein (CRP). We aggregated data from Canadian and European research studies to evaluate the associations of reduced food intake and CRP with cancer-associated WL (primary endpoint) and overall survival (OS, secondary endpoint)., Methods: The data set included a total of 12,253 patients at risk for cancer-associated WL. Patient-reported WL history (% in 6 months) and food intake (normal, moderately, or severely reduced) were measured in all patients; CRP (mg/L) and OS were measured in N = 4960 and N = 9952 patients, respectively. All measures were from a baseline assessment. Clinical variables potentially associated with WL and overall survival (OS) including age, sex, cancer diagnosis, disease stage, and performance status were evaluated using multinomial logistic regression MLR and Cox proportional hazards models, respectively., Results: Patients had a mean weight change of -7.3% (±7.1), which was categorized as: ±2.4% (stable weight; 30.4%), 2.5-5.9% (19.7%), 6.0-10.0% (23.2%), 11.0-14.9% (12.0%), ≥15.0% (14.6%). Normal food intake, moderately, and severely reduced food intake occurred in 37.9%, 42.8%, and 19.4%, respectively. In MLR, severe WL (≥15%) (vs. stable weight) was more likely (P < 0.0001) if food intake was moderately [OR 6.28, 95% confidence interval (CI 5.28-7.47)] or severely reduced [OR 18.98 (95% CI 15.30-23.56)]. In subset analysis, adjusted for food intake, CRP was independently associated (P < 0.0001) with ≥15% WL [CRP 10-100 mg/L: OR 2.00, (95% CI 1.58-2.53)] and [CRP > 100 mg/L: OR 2.30 (95% CI 1.62-3.26)]. Diagnosis, stage, and performance status, but not age or sex, were significantly associated with WL. Median OS was 9.9 months (95% CI 9.5-10.3), with median follow-up of 39.7 months (95% CI 38.8-40.6). Moderately and severely reduced food intake and CRP independently predicted OS (P < 0.0001)., Conclusions: Modelling WL as the dependent variable is an approach that can help to identify clinical features and biomarkers associated with WL. Here, we identify criterion values for food intake impairment and CRP that may improve the diagnosis and classification of cancer-associated cachexia., (© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.)

Published
2021
Full Text
View/download PDF

30. Reply to Caccialanza et al.

Author

Boisselier P, Thézénas S, Flori N, Vinches M, Bourhis J, and Senesse P

Subjects
Double-Blind Method, Humans, Chemoradiotherapy, Adjuvant, Head and Neck Neoplasms
Published
2021
Full Text
View/download PDF

31. Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study.

Author

Faravel K, Huteau ME, Jarlier M, de Forges H, Meignant L, Senesse P, Norton J, Jacot W, and Stoebner A

Subjects
Feasibility Studies, Female, Humans, Pain, Patient Education as Topic, Breast Neoplasms drug therapy, Yoga
Abstract

Background: Osteo-articular pain (OAP) is experienced by approximately 50% of women under hormonal therapy (HT) for breast cancer (BC), which increases the risk for therapy discontinuation. This study was aimed to assess benefits of yoga practice combined with patient education (PE) for at-home practice by evaluating feasibility among BC patients under HT and measuring OAP, flexibility and satisfaction., Methods: Feasibility was evaluated by patient adherence as accomplishment of at least 4 out of 6 supervised yoga-PE sessions along with 70% or more at-home yoga sessions. Intervention (12 weeks) included two 6-weeks periods: P1 comprising one 90-minutes supervised yoga-PE session/week and 15-minutes daily at-home yoga and P2, daily autonomous at-home yoga sessions. Evaluations (at inclusion and by the end of each period) consisted in assessment of OAP on Visual Analog Scale (VAS), forward flexibility (cm) and patient satisfaction on Likert (0-10 points) scale., Results: Between September 2018 and May 2019 we included 24 patients of median 53 years (range 36-72). Feasibility was validated by 83% successful adherence rate. Pain was significantly reduced from median VAS of 6 [range 4-10] to 4 [range 0-7] at the end of both P1 and P2 ( p  < 0.01), albeit with no difference between P1 and P2. Forward flexibility improved by a median gain of 8 cm (end of P2) and median satisfaction score of 10/10 [range 8-10]., Conclusion: Combined physiotherapy-yoga-PE intervention is a feasible strategy to increase at-home yoga practice with potential benefit on pain, flexibility, and satisfaction, thus prompting further evaluations in larger randomized multicenter trials., Clinicaltrials.gov: NCT04001751.

Published
2021
Full Text
View/download PDF

32. A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.

Author

Boisselier P, Kaminsky MC, Thézenas S, Gallocher O, Lavau-Denes S, Garcia-Ramirez M, Alfonsi M, Cupissol D, de Forges H, Janiszewski C, Geoffrois L, Sire C, and Senesse P

Subjects
Adult, Aged, Dietary Supplements, Double-Blind Method, Female, Humans, Male, Middle Aged, Young Adult, Chemoradiotherapy, Adjuvant, Food, Formulated, Head and Neck Neoplasms therapy, Immunologic Factors therapeutic use
Abstract

Background: In a previous phase II study an immunonutrient supplement was found to reduce severe acute toxicities for head and neck squamous cell cancer (HNSCC) patients treated with concomitant cisplatin and radiotherapy., Objectives: The primary objective of the present study was to evaluate efficacy of the same immunonutrient supplement on severe mucositis. Secondary objectives included tolerance, compliance to oral supplementation, chemotherapy interruptions and delays, quality of life, and progression-free survival (PFS) and overall survival (OS) at 1, 2, and 3 y., Methods: Between November 2009 and June 2013, 180 HNSCC patients eligible for adjuvant chemotherapy after surgery with curative intent were included in our double-blind phase III multicenter trial. They were assigned to receive oral supplementation (3 sachets/d) of either a formula enriched with l-arginine and omega-3 (n-3) fatty and ribonucleic acids (experimental arm), or an isocaloric isonitrogenous control (control arm), for 5 d before each of 3 cycles of cisplatin. Intention-to-treat (ITT) and per-protocol (PP) analyses were undertaken, along with subgroup analyses of ≥75% compliant patients, to compare the incidence of acute mucositis (Radiation Therapy Oncology Group and WHO scales) and 36-mo survival., Results: At 1 mo after terminating chemoradiotherapy (CRT), no differences were observed in the incidence of grade 3-4 mucositis between treatment groups, in the ITT, PP (172 patients), and subgroup (≥75% compliance, n = 112) analyses. The immunomodulating supplement did not significantly improve survival in the ITT and PP analyses at 3 y after CRT. Among ≥75% compliant patients, however, OS at 3 y was significantly improved in the immunomodulating formula group (81%; 95% CI: 67%, 89%) compared with controls (61%; 95% CI: 46%, 73%; P = 0.034), as well as PFS (73%; 95% CI: 58%, 83% compared with 50%; 95% CI: 36%, 63%; P = 0.012)., Conclusions: Although this immunomodulating formula failed to reduce severe mucositis during CRT, the findings suggest that the long-term survival of compliant HNSCC patients was improved.This trial was registered at clinicaltrials.gov as NCT01149642., (Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.)

Published
2020
Full Text
View/download PDF

33. Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial.

Author

Jacot W, Arnaud A, Jarlier M, Lefeuvre-Plesse C, Dalivoust P, Senesse P, Azzedine A, Tredan O, Sadot-Lebouvier S, Mas S, Carayol M, Bleuse JP, Gourgou S, Janiszewski C, Launay S, D'Hondt V, Lauridant G, Grenier J, Romieu G, Ninot G, and Vanlemmens L

Subjects
Breast Neoplasms complications, Female, Humans, Organization and Administration, Program Evaluation, Quality of Life, Treatment Outcome, Breast Neoplasms therapy, Chemoradiotherapy, Adjuvant adverse effects, Diet Therapy methods, Exercise Therapy methods, Fatigue etiology, Fatigue therapy, Health Education methods, Hospitals, Nutritional Physiological Phenomena physiology
Abstract

Supervised exercise dietary programs are recommended to relieve cancer-related fatigue and weight increase induced by adjuvant treatment of early breast cancer (EBC). As this recommendation lacks a high level of evidence, we designed a multicenter randomized trial to evaluate the impact of an Adapted Physical Activity Diet (APAD) education program on fatigue. We randomized 360 women with EBC who were receiving adjuvant chemotherapy and radiotherapy to APAD or usual care at eight French cancer institutions. Data were collected at baseline, end of chemotherapy, end of radiotherapy, and 6 months post-treatment. The primary endpoint was the general cancer-related fatigue score using the MFI-20 questionnaire. Fatigue correlated with the level of precariousness, but we found no significant difference between the two groups in terms of general fatigue ( p = 0.274). The APAD arm has a smaller proportion of patients with confirmed depression at the end of follow-up ( p = 0.052). A transient modification in physical activity levels and dietary intake was reported in the experimental arm. However, a mixed hospital- and home-based APAD education program is not enough to improve fatigue caused by adjuvant treatment of EBC. Cancer care centers should consider integrating more proactive diet-exercise supportive care in this population, focusing on precarious patients.

Published
2020
Full Text
View/download PDF

34. Complementary and Alternative Medicine in Patients With Breast Cancer: Exploratory Study of Social Network Forum Data.

Author

Lognos B, Carbonnel F, Boulze Launay I, Bringay S, Guerdoux-Ninot E, Mollevi C, Senesse P, and Ninot G

Abstract

Background: Patients and health care professionals are becoming increasingly preoccupied in complementary and alternative medicine (CAM) that can also be called nonpharmacological interventions (NPIs). In just a few years, this supportive care has gone from solutions aimed at improving the quality of life to solutions intended to reduce symptoms, supplement oncological treatments, and prevent recurrences. Digital social networks are a major vector for disseminating these practices that are not always disclosed to doctors by patients. An exploration of the content of exchanges on social networks by patients suffering from breast cancer can help to better identify the extent and diversity of these practices., Objective: This study aimed to explore the interest of patients with breast cancer in CAM from posts published in health forums and French-language social media groups., Methods: The retrospective study was based on a French database of 2 forums and 4 Facebook groups between June 3, 2006, and November 17, 2015. The extracted, anonymized, and compiled data (264,249 posts) were analyzed according to the occurrences associated with the NPI categories and NPI subcategories, their synonyms, and their related terms., Results: The results showed that patients with breast cancer use mainly physical (37.6%) and nutritional (31.3%) interventions. Herbal medicine is a subcategory that was cited frequently. However, the patients did not mention digital interventions., Conclusions: This exploratory study of the main French forums and discussion groups indicates a significant interest in CAM during and after treatments for breast cancer, with primarily physical and nutritional interventions complementing approved treatments. This study highlights the importance of accurate information (vs fake medicine), prescription and monitoring of these interventions, and the mediating role that health professionals must play in this regard., (©Béatrice Lognos, François Carbonnel, Isabelle Boulze Launay, Sandra Bringay, Estelle Guerdoux-Ninot, Caroline Mollevi, Pierre Senesse, Gregory Ninot. Originally published in JMIR Cancer (http://cancer.jmir.org), 27.11.2019.)

Published
2019
Full Text
View/download PDF

35. Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country.

Author

Senesse P, Isambert A, Janiszewski C, Fiore S, Flori N, Poujol S, Arroyo E, Courraud J, Guillaumon V, Mathieu-Daudé H, Colasse S, Baracos V, de Forges H, and Thezenas S

Subjects
Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Body Mass Index, Cachexia diagnosis, Cachexia economics, Cancer Care Facilities economics, Counseling, Disease Management, Health Care Costs, Hospitalization economics, Humans, Middle Aged, Neoplasms diagnosis, Neoplasms economics, Neoplasms therapy, Patient Care Team economics, Physicians economics, Practice Guidelines as Topic, Prevalence, Young Adult, Cachexia etiology, Cachexia therapy, Neoplasms complications, Nutritional Support
Abstract

Context: Cancer-associated cachexia is correlated with survival, side-effects, and alteration of the patients' well-being., Objectives: We implemented an institution-wide multidisciplinary supportive care team, a Cancer Nutrition Program (CNP), to screen and manage cachexia in accordance with the guidelines and evaluated the impact of this new organization on nutritional care and funding., Methods: We estimated the workload associated with nutrition assessment and cachexia-related interventions and audited our clinical practice. We then planned, implemented, and evaluated the CNP, focusing on cachexia., Results: The audit showed a 70% prevalence of unscreened cachexia. Parenteral nutrition was prescribed to patients who did not meet the guideline criteria in 65% cases. From January 2009 to December 2011, the CNP team screened 3078 inpatients. The screened/total inpatient visits ratio was 87%, 80%, and 77% in 2009, 2010, and 2011, respectively. Cachexia was reported in 74.5% (n = 2253) patients, of which 94.4% (n = 1891) required dietary counseling. Over three years, the number of patients with artificial nutrition significantly decreased by 57.3% (P < 0.001), and the qualitative inpatients enteral/parenteral ratio significantly increased: 0.41 in 2009, 0.74 in 2010, and 1.52 in 2011. Between 2009 and 2011, the CNP costs decreased significantly for inpatients nutritional care from 528,895€ to 242,272€, thus financing the nutritional team (182,520€ per year)., Conclusion: Our results highlight the great benefits of implementing nutritional guidelines through a physician-led multidisciplinary team in charge of nutritional care in a comprehensive cancer center., (Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

36. Patient-centeredness to anticipate and organize an end-of-life project for patients receiving at-home palliative care: a phenomenological study.

Author

Oude Engberink A, Badin M, Serayet P, Pavageau S, Lucas F, Bourrel G, Norton J, Ninot G, and Senesse P

Subjects
Aged, Aged, 80 and over, Attitude of Health Personnel, Cross-Sectional Studies, Decision Making, Female, France, Humans, Interviews as Topic, Male, Outcome Assessment, Health Care, Practice Patterns, Physicians' trends, Qualitative Research, General Practitioners ethics, Home Care Services organization & administration, Palliative Care organization & administration, Patient Participation statistics & numerical data, Terminal Care organization & administration
Abstract

Background: The development of end-of-life primary care is a socio-medical and ethical challenge. However, general practitioners (GPs) face many difficulties when initiating appropriate discussion on proactive shared palliative care. Anticipating palliative care is increasingly important given the ageing population and is an aim shared by many countries. We aimed to examine how French GPs approached and provided at-home palliative care. We inquired about their strategy for delivering care, and the skills and resources they used to devise new care strategies., Methods: Twenty-one GPs from the South of France recruited by phone according to their various experiences of palliative care agreed to participate. Semi-structured interview transcripts were examined using a phenomenological approach inspired by Grounded theory, and further studied with semiopragmatic analysis., Results: Offering palliative care was perceived by GPs as a moral obligation. They felt vindicated in a process rooted in the paradigm values of their profession. This study results in two key findings: firstly, their patient-centred approach facilitated the anticipatory discussions of any potential event or intervention, which the GPs openly discussed with patients and their relatives; secondly, this approach contributed to build an "end-of-life project" meeting patients' wishes and needs. The GPs all shared the idea that the end-of-life process required human presence and recommended that at-home care be coordinated and shared by multi-professional referring teams., Conclusions: The main tenets of palliative care as provided by GPs are a patient-centred approach in the anticipatory discussion of potential events, personalized follow-up with referring multi-professional teams, and the collaborative design of an end-of-life project meeting the aspirations of the patient and his or her family. Consequently, coordination strategies involving specialized teams, GPs and families should be modelled according to the specificities of each care system.

Published
2017
Full Text
View/download PDF

37. Meal context and food preferences in cancer patients: results from a French self-report survey.

Author

Guerdoux-Ninot E, Kilgour RD, Janiszewski C, Jarlier M, Meuric J, Poirée B, Buzzo S, Ninot G, Courraud J, Wismer W, Thezenas S, and Senesse P

Abstract

Purpose: The present study examined patient self-reports of descriptions, experiences and consequences of meal disturbances and food preferences within a cultural context (i.e., French meal traditions) in various treated cancer patients along their disease trajectory., Methods: Over 800 questionnaires were sent to 20 cancer treatment centres in France. During a 9-month period, 255 questionnaires were received from five centres. Inclusion criteria included those French patients over 18 years of age, could read and understand French, had an Eastern Cooperative Oncology Group score between 0 and 2, experienced treatment-induced nutrition changes and/or had decreased oral intake. Dietetic staff assessed clinical characteristics while patients completed a 17-item questionnaire., Results: The majority of patients were diagnosed with breast, gastro-intestinal (GI) tract and head and neck cancers (62 %). Half of the patients (49 %) experienced weight loss >5 %. The main treatment-induced side effects were fatigue, nausea, dry mouth, hypersensitivity to odors and GI tract transit disorders. These discomforts affected eating and drinking in 83 % of patients, inducing appetite loss and selected food aversion. Food preference appeared heterogeneous. Food taste, odor and finally appearance stimulated appetite. Finally, dietary behaviors and satisfaction were driven by the extent to which food was enjoyed., Conclusions: During oncologic treatments, eating and drinking were affected in more than three-quarters of patients. As recommended by practice guidelines, nutritional assessment and follow-up are required. Personalized nutritional counseling should include the role of the family, patient's meal traditions, and food habits.

Published
2016
Full Text
View/download PDF

38. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.

Author

Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, and Senesse P

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Body Composition, Body Surface Area, Canada epidemiology, Cohort Studies, Colonic Neoplasms drug therapy, Colonic Neoplasms epidemiology, Female, Fluorouracil adverse effects, Fluorouracil therapeutic use, France epidemiology, Humans, Leucovorin adverse effects, Leucovorin therapeutic use, Male, Middle Aged, Nervous System Diseases epidemiology, Organoplatinum Compounds adverse effects, Organoplatinum Compounds therapeutic use, Population Surveillance, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Body Mass Index, Colonic Neoplasms complications, Drug-Related Side Effects and Adverse Reactions epidemiology, Nervous System Diseases etiology
Abstract

Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose-limiting toxicity (DLT) in colon cancer patients. Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD). Muscle tissue was measured by computerized tomography (CT) and used to evaluate the LBM compartment of the whole body. In prospective randomized clinical trials conducted in France (n = 58), for patients given FOLFOX-based regimens according to body surface area, values of oxaliplatin/kg LBM were highly variable, ranging from 2.55 to 6.6 mg/kg LBM. A cut point of 3.09 mg oxaliplatin/kg LBM for developing toxicity was determined by Receiver Operating Characteristic (ROC) analysis, below this value 0/17 (0.0%) of patients experienced DLT; in contrast above this value 18/41 (44.0%) of patients were dose reduced or had treatment terminated owing to toxicity (≥Grade 3 or neuropathy ≥Grade 2); for 9/41 the DLT was sensory neuropathy. These findings were validated in an independent cohort of colon cancer patients (n = 80) receiving FOLFOX regimens as part of standard care, in Canada. Low LBM is a significant predictor of toxicity and neuropathy in patients administered FOLFOX-based regimens using conventional body surface area (BSA) dosing., (© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2016
Full Text
View/download PDF

39. A prospective observational study assessing home parenteral nutrition in patients with gastrointestinal cancer: benefits for quality of life.

Author

Senesse P, Tadmouri A, Culine S, Dufour PR, Seys P, Radji A, Rotarski M, Balian A, and Chambrier C

Subjects
Aged, Body Weight, Female, Gastrointestinal Neoplasms psychology, Humans, Male, Malnutrition psychology, Middle Aged, Nutritional Status, Patient Satisfaction, Prospective Studies, Surveys and Questionnaires, Treatment Outcome, Gastrointestinal Neoplasms diet therapy, Gastrointestinal Neoplasms physiopathology, Malnutrition diet therapy, Malnutrition physiopathology, Parenteral Nutrition, Home, Quality of Life
Abstract

Context: Patients with gastrointestinal cancer are at high risk for deterioration of nutrition. Home parenteral nutrition (HPN) could improve nutritional status and quality of life (QoL)., Objectives: The purpose of this study was 1) to evaluate the impact of HPN on QoL, 2) to assess changes in nutritional status, and 3) to assess proxy perception of patient well-being., Methods: We conducted a prospective, observational, and a multicenter study. Inclusion criteria were adult patients with gastrointestinal cancer, for whom HPN was indicated and prescribed for at least 14 days. The physician, the patient, and a family member completed questionnaires at inclusion and 28 days later. The QoL was assessed by the patients using the Functional Assessment of Cancer Therapy-General questionnaire, at inclusion and 28 days later., Results: The study included 370 patients with gastrointestinal cancer. The HPN was indicated for cancer-related undernutrition in 89% of the patients and was used as a complement to oral intake in 84%. After 28 days of parenteral intake, global QoL was significantly increased (48.9 at inclusion vs. 50.3, P=0.007). The patients' weight improved significantly by 2.7% (P<0.001). The nutrition risk screening also decreased significantly (3.2±1.1 vs. 2.8±1.3, P=0.003)., Conclusion: HPN could provide benefit for malnourished patients with gastrointestinal cancer. However, randomized controlled studies are required to confirm this benefit and the safety profile., (Copyright © 2015. Published by Elsevier Inc.)

Published
2015
Full Text
View/download PDF

40. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial.

Author

Bourdel-Marchasson I, Blanc-Bisson C, Doussau A, Germain C, Blanc JF, Dauba J, Lahmar C, Terrebonne E, Lecaille C, Ceccaldi J, Cany L, Lavau-Denes S, Houede N, Chomy F, Durrieu J, Soubeyran P, Senesse P, Chene G, and Fonck M

Subjects
Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Cachexia, Counseling, Diet, Energy Intake, Female, Humans, Male, Nutritional Status, Weight Loss, Antineoplastic Agents adverse effects, Malnutrition mortality, Neoplasms drug therapy, Neoplasms mortality
Abstract

Objective: We tested the effect of dietary advice dedicated to increase intake in older patients at risk for malnutrition during chemotherapy, versus usual care, on one-year mortality., Method: We conducted a multicentre, open-label interventional, stratified (centre), parallel randomised controlled trial, with a 1∶1 ratio, with two-year follow-up. Patients were aged 70 years or older treated with chemotherapy for solid tumour and at risk of malnutrition (MNA, Mini Nutritional Assessment 17-23.5). Intervention consisted of diet counselling with the aim of achieving an energy intake of 30 kCal/kg body weight/d and 1.2 g protein/kg/d, by face-to-face discussion targeting the main nutritional symptoms, compared to usual care. Interviews were performed 6 times during the chemotherapy sessions for 3 to 6 months. The primary endpoint was 1-year mortality and secondary endpoints were 2-year mortality, toxicities and chemotherapy outcomes., Results: Between April 2007 and March 2010 we randomised 341 patients and 336 were analysed: mean (standard deviation) age of 78.0 y (4·9), 51.2% male, mean MNA 20.2 (2.1). Distribution of cancer types was similar in the two groups; the most frequent were colon (22.4%), lymphoma (14.9%), lung (10.4%), and pancreas (17.0%). Both groups increased their dietary intake, but to a larger extent with intervention (p<0.01). At the second visit, the energy target was achieved in 57 (40.4%) patients and the protein target in 66 (46.8%) with the intervention compared respectively to 13 (13.5%) and 20 (20.8%) in the controls. Death occurred during the first year in 143 patients (42.56%), without difference according to the intervention (p = 0.79). No difference in nutritional status changes was found. Response to chemotherapy was also similar between the groups., Conclusion: Early dietary counselling was efficient in increasing intake but had no beneficial effect on mortality or secondary outcomes. Cancer cachexia antianabolism may explain this lack of effect., Trial Registration: ClinicalTrials.gov NCT00459589.

Published
2014
Full Text
View/download PDF

41. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

Author

Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, and Assenat E

Subjects
Adult, Aged, Aged, 80 and over, CA-19-9 Antigen metabolism, Deoxycytidine therapeutic use, Disease Progression, Disease-Free Survival, Female, Humans, Male, Middle Aged, Retrospective Studies, Gemcitabine, Antimetabolites, Antineoplastic therapeutic use, Deoxycytidine analogs & derivatives, Neoplasm Metastasis pathology, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology
Abstract

Aim: To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastatic pancreatic cancer [(frequency, response, outcome, course of carbohydrate antigen 19-9 (CA 19-9)]., Methods: This retrospective study included all patients with advanced or metastatic pancreatic cancer (adenocarcinoma or carcinoma) treated with second-line chemotherapy in our center between 2000 and 2008. All patients received first-line chemotherapy with gemcitabine, and prior surgery or radiotherapy was permitted. We analyzed each chemotherapy protocol for second-line treatment, the number of cycles and the type of combination used. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, response rate, grade 3-4 toxicity, dosage modifications and CA 19-9 course., Results: A total of eighty patients (38%) underwent a second-line therapy among 206 patients who had initially received first-line treatment with a gemcitabine-based regimen. Median number of cycles was 4 (range: 1-12) and the median duration of treatment was 2.6 mo (range: 0.3-7.4). The overall disease control rate was 40.0%. The median overall survival and progression-free survival from the start of second-line therapy were 5.8 (95% CI: 4.1-6.6) and 3.4 mo (95% CI: 2.4-4.2), respectively. Toxicity was generally acceptable. Median overall survival of patients with a CA 19-9 level declining by more than 20% was 10.3 mo (95% CI: 4.5-11.6) vs 5.2 mo (95% CI: 4.0-6.4) for others (P = 0.008)., Conclusion: A large proportion of patients could benefit from second-line therapy, and CA 19-9 allows efficient treatment monitoring both in first and second-line chemotherapy.

Published
2012
Full Text
View/download PDF

42. Tobacco use and associations of beta-carotene and vitamin intakes with colorectal adenoma risk.

Author

Senesse P, Touvier M, Kesse E, Faivre J, and Boutron-Ruault MC

Subjects
Adenoma prevention & control, Adult, Case-Control Studies, Colorectal Neoplasms prevention & control, Female, Humans, Male, Middle Aged, Risk Factors, Risk Reduction Behavior, Adenoma epidemiology, Colorectal Neoplasms epidemiology, Smoking epidemiology, Vitamins administration & dosage, beta Carotene administration & dosage
Abstract

The effects of vitamins and beta-carotene on the risk of colorectal adenomas have not been fully investigated. Recent data suggest that smoking could modulate the effect of beta-carotene supplements on adenoma recurrence. We investigated the effect of dietary vitamins and beta-carotene on the risk of adenomas, and a potential interaction with smoking status as part of a case-control study of environmental factors associated with the risk of colorectal adenomas and cancers. We compared nutrient intakes in polyp-free controls (n = 427) and adenoma cases (n = 362) globally and using models stratified by smoking status, adjusted for age, sex, BMI, and energy and alcohol intakes. Folate and vitamins C and B-6 were inversely related to adenoma risk (P for trend = 0.005, 0.03, and 0.02, respectively), whereas vitamin D tended to be inversely associated with risk (P for trend = 0.05). There was a significant interaction between beta-carotene and smoking (P interaction = 0.04). In nonsmokers, beta-carotene was inversely associated with adenoma risk, especially that of colon adenomas [odds ratios (ORs) in low vs. high consumers and 95% CI 0.4 (0.2-0.9)], whereas in past or current smokers, beta-carotene was associated with a nonsignificant (P for trend = 0.19) increase in the risk of colon adenomas [corresponding OR = 1.9 (95% CI = 0.9-4.1)]. Our findings support a protective effect of folate and vitamins C and B-6 irrespective of smoking habits, and a protective effect of beta-carotene in nonsmokers only. They suggest an adverse effect of beta-carotene in smokers, who should be cautious about taking high doses of this micronutrient.

Published
2005
Full Text
View/download PDF

43. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.

Author

Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pèlegrin A, Dubois JB, and Thèzenas S

Subjects
Adult, Aged, Aged, 80 and over, Biopsy, Combined Modality Therapy, Disease Progression, Disease-Free Survival, Dose-Response Relationship, Radiation, Female, Humans, Immunohistochemistry, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Prognosis, Proportional Hazards Models, Recurrence, Regression Analysis, Risk, Time Factors, Treatment Outcome, Biomarkers, Tumor, ErbB Receptors biosynthesis, Radiotherapy methods, Rectal Neoplasms pathology, Rectal Neoplasms radiotherapy, Rectal Neoplasms surgery
Abstract

Background: Epidermal growth factor receptor (EGFR) represents a major target for current radiosensitizing strategies. We wished to ascertain whether a correlation exists between the expression of EGFR and treatment outcome in a group of patients with rectal adenocarcinoma who had undergone preoperative radiotherapy (RT)., Methods: Within a six-year period, 138 patients underwent preoperative radiotherapy and curative surgery for rectal cancer (UICC stages II-III) at our institute. Among them, 77 pretherapeutic tumor biopsies were available for semi-quantitative immunohistochemical investigation evaluating the intensity and the number (extent) of tumor stained cells. Statistical analyses included Cox regression for calculating risk ratios of survival endpoints and logistic regression for determining odds ratios for the development of loco-regional recurrences., Results: Median age was 64 years (range: 30-88). Initial staging showed 75% and 25% stage II and III tumors, respectively. RT consisted of 44-Gy pelvic irradiation in 2-Gy fractions using 18-MV photons. In 25 very low-rectal-cancer patients the primary tumor received a boost dose of up to 16 Gy for a sphincter-preservation approach. Concomitant chemotherapy was used in 17% of the cases. All patients underwent complete total mesorectal resection. Positive staining (EGFR+) was observed in 43 patients (56%). Median follow-up was 36 months (range: 6-86). Locoregional recurrence rates were 7 and 20% for EGFR extent inferior and superior to 25%, respectively. The corresponding locoregional recurrence-free survival rate at two years was 94% (95% confidence interval, CI, 92-98%) and 84% (CI 95%, 58-95%), respectively (P = 0.06). Multivariate analyses showed a significant correlation between the rate of loco-regional recurrence and three parameters: EGFR extent superior to 25% (hazard ratio = 7.18, CI 95%, 1.17-46, P = 0.037), rectal resection with microscopic residue (hazard ratio = 6.92, CI 95%, 1.18-40.41, P = 0.032), and a total dose of 44 Gy (hazard ratio = 5.78, CI 95%, 1.04-32.05, P = 0.045)., Conclusion: EGFR expression impacts on loco-regional recurrence. Knowledge of expression of EGFR in rectal cancer could contribute to the identification of patients with an increased risk of recurrences, and to the prediction of prognosis.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results